Bridgebio Stock Today

BBIO -  USA Stock  

USD 6.63  0.61  8.43%

Market Performance
1 of 100
Odds Of Distress
Over 75
Bridgebio Pharma is selling for 6.63 as of the 28th of May 2022. This is a -8.43% down since the beginning of the trading day. The stock's open price was 7.24. Bridgebio Pharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Bridgebio Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of April 2022 and ending today, the 28th of May 2022. Click here to learn more.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 147.19 M outstanding shares of which 19.4 M shares are currently shorted by private and institutional investors with about 10.14 trading days to cover. More on Bridgebio Pharma
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Bridgebio Pharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Bridgebio Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bridgebio Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Bridgebio Pharma has very high historical volatility over the last 90 days
Bridgebio Pharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 69.72 M. Net Loss for the year was (562.54 M) with profit before overhead, payroll, taxes, and interest of 66.6 M.
Bridgebio Pharma currently holds about 836.66 M in cash with (497.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67.
Bridgebio Pharma has a poor financial position based on the latest SEC disclosures
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.fiercebiotech.com: Flagship-run ProFound unveils with 75M to develop protein trove - FierceBiotech
Bridgebio Pharma Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Bridgebio Pharma SEC Filings
Bridgebio Pharma SEC Filings Security & Exchange Commission EDGAR Reports
Thematic Classification
Currently Active Investing Idea (view all)
Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Bridgebio Pharma report their recommendations after researching Bridgebio Pharma's financial statements, talking to executives and customers, or listening in on Bridgebio Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Bridgebio Pharma. The Bridgebio consensus assessment is calculated by taking the average forecast from all of the analysts covering Bridgebio Pharma.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Bridgebio Pharma based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Bridgebio Pharma financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares129.2 M144.4 M
Moderately Down
Increasing
Slightly volatile
Weighted Average Shares Diluted129.2 M144.4 M
Moderately Down
Increasing
Slightly volatile
Total Assets870.1 MB
Fairly Down
Increasing
Slightly volatile
Total LiabilitiesB1.9 B
Significantly Up
Increasing
Slightly volatile
Current Assets773.8 M888.9 M
Fairly Down
Increasing
Slightly volatile
Current Liabilities109.6 M135.1 M
Significantly Down
Increasing
Slightly volatile
Total Debt1.9 B1.7 B
Significantly Up
Increasing
Slightly volatile
Gross Margin1.060.955
Significantly Up
Increasing
Slightly volatile
Asset Turnover0.05950.07
Fairly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bridgebio Pharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Bridgebio Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Bridgebio Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bridgebio Pharma's financial leverage. It provides some insight into what part of Bridgebio Pharma's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Bridgebio Pharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Bridgebio Pharma deploys its capital and how much of that capital is borrowed.
Liquidity
Bridgebio Pharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 1.73 B in liabilities with Debt to Equity (D/E) ratio of 4.61, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bridgebio Pharma has a current ratio of 6.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Bridgebio Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Bridgebio Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bridgebio Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bridgebio to invest in growth at high rates of return. When we think about Bridgebio Pharma's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(511.04 Million)Share
Bridgebio Pharma (BBIO) is traded on NASDAQ Exchange in USA. It is located in 421 Kipling Street and employs 576 people. Bridgebio Pharma is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.12 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bridgebio Pharma's market, we take the total number of its shares issued and multiply it by Bridgebio Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Bridgebio Pharma conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 147.19 M outstanding shares of which 19.4 M shares are currently shorted by private and institutional investors with about 10.14 trading days to cover. Bridgebio Pharma currently holds about 836.66 M in cash with (497.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67.
Check Bridgebio Pharma Probability Of Bankruptcy
Ownership
Bridgebio Pharma retains a total of 147.19 Million outstanding shares. The majority of Bridgebio Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bridgebio Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bridgebio Pharma. Please pay attention to any change in the institutional holdings of Bridgebio Pharma as this could imply that something significant has changed or about to change at the company. Also note that nearly two million nine hundred fourty-three thousand eight hundred invesors are currently shorting Bridgebio Pharma expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Bridgebio Ownership Details

Bridgebio Stock Price Odds Analysis

What are Bridgebio Pharma's target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Bridgebio Pharma jumping above the current price in 90 days from now is about 90.03%. The Bridgebio Pharma probability density function shows the probability of Bridgebio Pharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.236 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bridgebio Pharma will likely underperform. Additionally, the company has an alpha of 0.0502, implying that it can generate a 0.0502 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 6.63HorizonTargetOdds Above 6.63
9.93%90 days
 6.63 
90.03%
Based on a normal probability distribution, the odds of Bridgebio Pharma to move above the current price in 90 days from now is about 90.03 (This Bridgebio Pharma probability density function shows the probability of Bridgebio Stock to fall within a particular range of prices over 90 days) .

Bridgebio Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Bridgebio Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bridgebio Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bridgebio Pharma's value.
InstituionSecurity TypeTotal SharesValue
Kohlberg Kravis Roberts Co LpCommon Shares31.1 M315.3 M
Viking Global Investors LpCommon Shares26.6 M270.2 M
Aristeia Capital LlcDebt100.2 M60.1 M
View Bridgebio Pharma Diagnostics

Bridgebio Pharma Historical Income Statement

Bridgebio Pharma Income Statement is one of the three primary financial statements used for reporting Bridgebio's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bridgebio Pharma revenue and expense. Bridgebio Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Interest Expense is expected to rise to about 50.5 M this year, although the value of Consolidated Income will most likely fall to (601.9 M). View More Fundamentals

Bridgebio Stock Against Markets

Picking the right benchmark for Bridgebio Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bridgebio Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bridgebio Pharma is critical whether you are bullish or bearish towards Bridgebio Pharma at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bridgebio Pharma without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Volatility Analysis Now

   

Volatility Analysis

Get historical volatility and risk analysis based on latest market data
All  Next Launch Module

Investing Bridgebio Pharma

You need to understand the risk of investing before taking a position in Bridgebio Pharma. The danger of trading Bridgebio Pharma is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bridgebio Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bridgebio Pharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bridgebio Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Bridgebio Pharma information on this page should be used as a complementary analysis to other Bridgebio Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Bridgebio Stock analysis

When running Bridgebio Pharma price analysis, check to measure Bridgebio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridgebio Pharma is operating at the current time. Most of Bridgebio Pharma's value examination focuses on studying past and present price action to predict the probability of Bridgebio Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bridgebio Pharma's price. Additionally, you may evaluate how the addition of Bridgebio Pharma to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Bridgebio Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bridgebio Pharma. If investors know Bridgebio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bridgebio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bridgebio Pharma is measured differently than its book value, which is the value of Bridgebio that is recorded on the company's balance sheet. Investors also form their own opinion of Bridgebio Pharma's value that differs from its market value or its book value, called intrinsic value, which is Bridgebio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bridgebio Pharma's market value can be influenced by many factors that don't directly affect Bridgebio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bridgebio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Bridgebio Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bridgebio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.